Manufacturer of Controlled Substances; Notice of Registration, 2160-2161 [2010-512]
Download as PDF
<![CDATA[
pwalker on DSK8KYBLC1PROD with NOTICES
2160
Federal Register / Vol. 75, No. 9 / Thursday, January 14, 2010 / Notices
section 337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337 (‘‘section
337’’).
FOR FURTHER INFORMATION CONTACT:
James A. Worth, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street, SW.,
Washington, DC 20436, telephone (202)
205–3065. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street, SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: This
investigation was instituted on March
31, 2008, based upon a complaint filed
on behalf of General Electric Company
of Fairfield, Connecticut (‘‘GE’’) on
February 7, 2008. 73 FR 16910. The
complaint alleged violations of section
337 of the Tariff Act of 1930 (19 U.S.C.
1337) in the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain variable speed
wind turbines and components thereof
that infringe claims 121–125 of U.S.
Patent No. 5,083,039 (‘‘the ‘039 patent’’)
and claims 1–12, 15–18, and 21–28 of
U.S. Patent No. 6,921,985 (‘‘the ‘985
patent’’). The complaint named as
respondents Mitsubishi Heavy
Industries, Ltd. of Tokyo, Japan (‘‘MHI’’);
Mitsubishi Power Systems, Inc. of Lake
Mary, Florida (‘‘MPSA’’); and Mitsubishi
Heavy Industries America, Inc. of New
York, New York (‘‘MHIA’’). On October
8, 2008, the Commission issued notice
of its determination not to review an
initial determination (‘‘ID’’) (Order No.
10) granting GE’s motion to amend its
complaint and the notice of
investigation to add claims 1–19 of U.S.
Patent No. 7,321,221 (‘‘the ‘221 patent’’)
to this investigation.
On August 7, 2009, the ALJ issued a
final ID finding a violation of section
337 in this investigation. The ALJ found
that there was a violation in the sale for
importation, importation, or sale after
importation by respondents MHI and
MPSA with respect to claim 121 of the
‘039 patent and claim 15 of the ‘985
VerDate Nov<24>2008
17:36 Jan 13, 2010
Jkt 220001
patent. The ALJ found that there was no
violation with respect to these claims by
MHIA. The ALJ also found that there
was no violation of section 337 by any
party with respect to claims 5, 7, and 8
of the ‘221 patent.
On August 24, 2009, the Commission
received petitions and/or contingent
petitions for review from: (1) MHI,
MPSA, and MHIA; (2) GE; and (3) the
Commission investigative attorney. On
September 1, 2009, each of the parties
filed responses thereto.
On October 8, 2009, the Commission
issued notice of its determination to
review the final ID, except with respect
to the issue of importation and the
intent finding underlying the ALJ’s
inequitable conduct determination. 72
FR 52975 (Oct. 15, 2009). The
Commission requested briefing on the
issues on review, including certain
specific questions, in addition to
remedy, the public interest, and
bonding.
On October 23, 2009, the Commission
issued notice of its determination to
extend the deadline for public
submissions on remedy, the public
interest, and bonding to November 2,
2009, and for all responses to all
remedy, the public interest, and
bonding submissions to November 9,
2009.
On October 22, 2009, Mitsubishi, GE,
the IA, and Iberdrola filed submissions
in response to the notice of review. On
October 30, 2009, Turner Bros., LLC
filed a submission on remedy. On
November 2, 2009, Mitsubishi, GE, and
the IA filed reply submissions on
violation. On November 9, 2009,
Mitsubishi, GE, the IA, and Iberdrola
filed reply submissions on remedy.
Having reviewed the final ID, the
submissions on review, and the record,
the Commission has determined to
terminate the investigation with a final
determination of no violation. A
Commission opinion will issue shortly.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and under sections 210.42–.51 of the
Commission’s Rules of Practice and
Procedure (19 CFR 210.42–.51).
Issued: January 8, 2010.
By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. 2010–499 Filed 1–13–10; 8:45 am]
BILLING CODE 7020–02–P
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated August 21, 2009, and
published in the Federal Register on
September 8, 2009 (74 FR 46232),
Alltech Associates Inc., 2051 Waukegan
Road, Deerfield, Illinois 60015, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
4-Methylaminorex (cis isomer)
(1590).
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
4-Methoxyamphetamine (7411) ...
Alpha-methyltryptamine (7432) ....
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
N-Ethyl-1-phenylcyclohexylamine
(7455).
1-(1-Phenylcyclohexyl)pyrrolidine
(7458).
1-Phenylcyclohexylamine (7460)
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
Normorphine (9313) .....................
Methamphetamine (1105) ............
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
E:\FR\FM\14JAN1.SGM
14JAN1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
Federal Register / Vol. 75, No. 9 / Thursday, January 14, 2010 / Notices
Drug
Schedule
1-Piperidinocyclohexanecarbonitrile (8603).
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Dihydromorphine (9145) ...............
Ecgonine (9180) ...........................
Meperidine intermediate-B (9233)
Noroxymorphone (9668) ..............
II
II
II
II
II
II
II
II
The company plans to manufacture
high purity drug standards used for
analytical application only in clinical,
toxicological, and forensic laboratories.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Alltech Associates to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Alltech Associates to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–512 Filed 1–13–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employee Benefits Security
Administration
Proposed Extension of Information
Collection; Comment Request;
Employee Benefit Plan Claims
Procedures Under ERISA
pwalker on DSK8KYBLC1PROD with NOTICES
AGENCY: Employee Benefits Security
Administration, Department of Labor.
ACTION: Notice.
SUMMARY: The Department of Labor (the
Department), in accordance with the
Paperwork Reduction Act of 1995 (PRA
95) (44 U.S.C. 3506(c)(2)(A)), provides
the general public and Federal agencies
with an opportunity to comment on
proposed and continuing collections of
information. This helps the Department
VerDate Nov<24>2008
17:36 Jan 13, 2010
Jkt 220001
assess the impact of its information
collection requirements and minimize
the reporting burden on the public and
the public understand the Department’s
information collection requirements and
provide the requested data in the
desired format. Currently, the Employee
Benefits Security Administration
(EBSA) is soliciting comments on a
proposed extension of the current
approval of information collection
provisions incorporated in the
regulation pertaining to employee
benefit plan claims procedures under
the Employee Retirement Income
Security Act of 1974 (ERISA). A copy of
the information collection request (ICR)
may be obtained by contacting the office
listed in the ADDRESSES section of this
notice.
DATES: Written comments must be
submitted on or before March 15, 2010.
ADDRESSES: Direct all written comments
to G. Christopher Cosby, Office of Policy
and Research, Employee Benefits
Security Administration, U.S.
Department of Labor, 200 Constitution
Avenue, NW., Room N–5647,
Washington, DC 20210. Telephone:
(202) 693–8410; Fax: (202) 219–4745.
These are not toll-free numbers.
Comments may also be submitted
electronically to the following Internet
e-mail address: ebsa.opr@dol.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 503 of ERISA requires each
employee benefit plan to provide,
pursuant to regulations promulgated by
the Secretary of Labor, notice in writing
to any participant or beneficiary whose
claim for benefits under the plan has
been denied. The notice must set forth
the specific reasons for the denial and
must be written in a manner calculated
to be understood by the claimant. Plans
must also give a participant or
beneficiary whose claim has been
denied a reasonable opportunity to
obtain a full and fair review of any
benefit claim denial by the appropriate
named fiduciary.
The Department issued a regulation
pertaining to benefit claims procedures
in 1977 and amended that regulation in
a Notice of Final Rulemaking (NFRM)
published on November 21, 2000 (65 FR
70246). The regulation pertaining to
benefit claims procedures is codified at
29 CFR 2560.503–1. The regulation
requires plans to establish reasonable
claims procedures that meet specified
standards governing the timing and
content of notices and disclosures.
EBSA submitted an ICR for the
information collections in 29 CFR
2560.503–1 to the Office of Management
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
2161
and Budget (OMB) for review and
clearance in connection with
publication of the NFRM, and OMB
approved the information collections
under OMB control number 1210–0053.
That approval is scheduled to expire on
April 30, 2010. After considering
comments received in response to this
notice, the Department intends to
submit an ICR to OMB to request
continuing approval. The public is not
required to respond to an information
collection unless it displays a valid
control number. No change to the
existing ICR is being proposed or made
at this time.
II. Desired Focus of Comments
The Department of Labor
(Department) is particularly interested
in comments that
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
III. Current Action
This notice requests comments on an
extension of OMB’s approval of the
information collections included in 29
CFR 2560.503–1. The Department is not
proposing or implementing changes to
the existing ICR at this time. A summary
of the ICR and the current burden
estimates follows:
Agency: Employee Benefits Security
Administration, Department of Labor.
Title: Employee Benefit Plan Claims
Procedures under ERISA.
Type of Review: Extension of a
currently approved collection of
information.
OMB Number: 1210–0053.
Affected Public: Business or other forprofit; not-for-profit institutions.
Respondents: 5,900,000.
Responses: 321,000,000.
Estimated Total Burden Hours:
529,000.
E:\FR\FM\14JAN1.SGM
14JAN1
]]>Agencies
[Federal Register Volume 75, Number 9 (Thursday, January 14, 2010)]
[Notices]
[Pages 2160-2161]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-512]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated August 21, 2009, and published in the Federal
Register on September 8, 2009 (74 FR 46232), Alltech Associates Inc.,
2051 Waukegan Road, Deerfield, Illinois 60015, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the basic classes of controlled substances
listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
N,N-Dimethylamphetamine (1480)............. I
4-Methylaminorex (cis isomer) (1590)....... I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
2,5-Dimethoxy-4-(n)- I
propylthiophenethylamine (7348).
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
2,5-Dimethoxy-4-ethylamphetamine (7399).... I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (MDMA) I
(7405).
4-Methoxyamphetamine (7411)................ I
Alpha-methyltryptamine (7432).............. I
Bufotenine (7433).......................... I
Diethyltryptamine (7434)................... I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
5-Methoxy-N,N-diisopropyltryptamine (7439). I
N-Ethyl-1-phenylcyclohexylamine (7455)..... I
1-(1-Phenylcyclohexyl)pyrrolidine (7458)... I
1-Phenylcyclohexylamine (7460)............. I
1-[1-(2-Thienyl)cyclohexyl]piperidine I
(7470).
Normorphine (9313)......................... I
Methamphetamine (1105)..................... II
Phencyclidine (7471)....................... II
Phenylacetone (8501)....................... II
[[Page 2161]]
1-Piperidinocyclohexane- carbonitrile II
(8603).
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Dihydromorphine (9145)..................... II
Ecgonine (9180)............................ II
Meperidine intermediate-B (9233)........... II
Noroxymorphone (9668)...................... II
------------------------------------------------------------------------
The company plans to manufacture high purity drug standards used
for analytical application only in clinical, toxicological, and
forensic laboratories.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Alltech Associates to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Alltech Associates to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: January 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-512 Filed 1-13-10; 8:45 am]
BILLING CODE 4410-09-P
